- Home
- OUST vs CTMX Comparison
OUST vs CTMX Comparison
Compare OUST & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OUST | CTMX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 977.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | OUST | CTMX |
|---|---|---|
| Price | $26.77 | $4.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $39.25 | $12.10 |
| AVG Volume (30 Days) | 1.8M | ★ 3.9M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $33.20 | N/A |
| Revenue Next Year | $37.27 | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.65 | $0.76 |
| 52 Week High | $41.65 | $8.21 |
Technical Indicators
Market Signals| Indicator | OUST | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 61.51 | 43.21 |
| Support Level | $21.03 | $4.02 |
| Resistance Level | $30.10 | $4.33 |
| Average True Range (ATR) | 1.95 | 0.27 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 67.81 | 22.48 |
Price Performance
Historical ComparisonAbout OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.